Razdan Sanjay, Johannes James, Cox Michael, Bagley Demetrius H
Department of Urology, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
J Endourol. 2005 Apr;19(3):366-71. doi: 10.1089/end.2005.19.366.
To determine the current practice patterns in the management of upper-tract transitional-cell carcinoma (TCC) among a large group of urologists.
A survey was sent to 220 practicing members of the Society of Urologic Oncology (SUO) and the Endourological Society (ES) and members of the American Urological Association who did not belong to either society. The survey consisted of 16 focused questions pertaining to the surveillance and management of upper-tract TCC. The responses were used to create a database, which was then analyzed to determine practice trends.
Eighty-four of the urologists responded, for a response rate of 38%. Fourteen responses were excluded because of multiple answers to a given question, so 70 were included in the final analysis. Eighty percent of the respondents were in academic practice. A CT urogram was the favored initial procedure for diagnosis of upper-tract TCC and an intravenous urogram was the next commonest choice (53% and 40%, respectively). Ureterorenoscopy was the surveillance tool of choice (70%) after conservative treatment of upper- tract TCC. Laparoscopic nephroureterectomy was the preferred procedure (73%) for a high-grade, large renal-pelvic TCC. Twenty-one percent of the endourologists recommended ureteroscopic ablation for a high-grade, large distal ureteral tumor. This was in sharp contrast to 77% of the respondents who favored a distal ureterectomy for the same clinical scenario.
This study confirms that most urologists treating upper-tract TCC follow the principles reported in the published literature regarding the management of these patients. Further, most urologists, regardless of society affiliations or years in practice, favor minimally invasive techniques for the management of upper-tract TCC. This information may be useful in formulating clear guidelines for the management of this disease.
确定一大群泌尿外科医生在上尿路移行细胞癌(TCC)管理方面的当前实践模式。
向220名泌尿外科肿瘤学会(SUO)和腔内泌尿外科协会(ES)的执业会员以及不属于这两个协会的美国泌尿外科协会会员发送了一份调查问卷。该调查问卷包含16个与上尿路TCC监测和管理相关的重点问题。收集到的回复用于创建一个数据库,然后对其进行分析以确定实践趋势。
84名泌尿外科医生回复了问卷,回复率为38%。由于对给定问题有多个答案,14份回复被排除,因此最终分析纳入了70份回复。80%的受访者从事学术工作。CT尿路造影是诊断上尿路TCC最常用的初始检查方法,静脉尿路造影是第二常见的选择(分别为53%和40%)。输尿管镜检查是上尿路TCC保守治疗后首选的监测工具(70%)。腹腔镜肾输尿管切除术是高级别、大的肾盂TCC的首选手术方式(73%)。21%的腔内泌尿外科医生推荐对高级别、大的远端输尿管肿瘤进行输尿管镜下消融。这与77%的受访者在相同临床情况下倾向于行远端输尿管切除术形成鲜明对比。
本研究证实,大多数治疗上尿路TCC的泌尿外科医生遵循已发表文献中报道的关于这些患者管理的原则。此外,大多数泌尿外科医生,无论所属协会或从业年限如何,都倾向于采用微创技术来管理上尿路TCC。这些信息可能有助于制定关于该疾病管理的明确指南。